Stoke Therapeutics, Inc.
NASDAQ:STOKBiotechnology
-$0.34 today
- Market cap
- $1.76B
- Beta
- 1.19
- P/E (TTM)
- -11.1
- EPS (TTM)
- -$2.69
Volume 0.64M
Average 0.64M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Stoke Therapeutics, Inc.
NASDAQ:STOK
Intrinsic Alpha fair value
Locked
Current Price
$26.93
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A3 analysts |
| Revenue | N/A | N/A | +145.9% | +27.1% (5yr)5 analysts |
| Net Income | N/A | N/A | N/A | N/A5 analysts |
| EBIT | N/A | N/A | N/A | N/A5 analysts |
Analysis
Recent growth has been strongest in Revenue at +145.9% over three years. Forward estimates point to Revenue at +27.1% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Ionis Pharmaceuticals, Inc. NASDAQ:IONS | $4.84B | $29.06 | Not rated | -37.5 | -63.22% |
Beam Therapeutics Inc. NASDAQ:BEAM | $2.36B | $22.83 | Not rated | -52.3 | -0.19% |
Silence Therapeutics plc NASDAQ:SLN | $936.65M | $19.83 | Not rated | -3.9 | +208.09% |
Design Therapeutics, Inc. NASDAQ:DSGN | $670.46M | $10.47 | Not rated | -10.7 | +26.98% |
Wave Life Sciences Ltd. NASDAQ:WVE | $617.33M | $3.13 | Not rated | -6.6 | -60.47% |
ProQR Therapeutics N.V. NASDAQ:PRQR | $198.98M | $1.41 | Not rated | -3.8 | -48.28% |
Continue the stock analysis
Jump to another research area for this company.